Table I.
Patient characteristics and vaccination data
| Characteristic | All patients | LPhS | No LPhS | P value |
|---|---|---|---|---|
| No. of patients | 158 | 61 (38.6) | 97 (61.4) | |
| Age at vaccination (years), mean ± SD | 44.8 ± 15.8 | 47.6 ± 12.9 | 43.1 ± 17.3 | .06 |
| Sex | .02 | |||
| Female | 34 (85) | 57 (93.4) | 77 (79.4) | |
| Male | 24 (15) | 4 (6.6) | 20 (20.6) | |
| Race | .57∗ | |||
| White | 93 (59) | 38 (62.3) | 55 (56.7) | |
| African American/Black | 19 (12) | 7 (11.5) | 12 (12.4) | |
| Asian | 12 (8) | 3 (4.9) | 9 (9.3) | |
| Native American/Alaskan/Pacific Islander | 2 (1) | 0 | 2 (2) | |
| Unknown/declined | 32 (20) | 13 (21.3) | 19 (19.6) | |
| Ethnicity | .06 | |||
| Hispanic | 20 (13) | 6 (9.8) | 14 (14.4) | |
| Non-Hispanic | 117 (74) | 42 (68.9) | 75 (77.3) | |
| Unknown | 21 (13) | 13 (21.3) | 8 (8.3) | |
| Type of COVID-19 vaccine received | .001 | |||
| BNT162b2 | 100 (63.3) | 48 (78.7) | 52 (53.6) | |
| mRNA1-1273 | 56 (35.4) | 12 (19.7) | 44 (45.4) | |
| Janssen† | 2 (1.3) | 1 (1.6) | 1 (1) | NA |
| Vaccine dose that caused initial reaction | .5 | |||
| First | 135 (85.4) | 52 (85.2) | 83 (85.6) | |
| Second | 17 (10.8) | 8 (13.1) | 9 (9.3) | |
| Booster (third) | 6 (3.8) | 1 (1.6) | 5 (5.2) | |
| Exact dates for first and second mRNA vaccination available | 122 (77.2) | 51 (83.6) | 71 (73.2) | |
| Second dose of mRNA vaccine delayed (>6 weeks) | 67 (54.9) | 36 (70.6) | 31 (43.7) | .0032 |
| No delay in vaccination | 55 (45.1) | 15 (29.4) | 40 (56.3) |
Data are presented as nos. (%) unless otherwise indicated.
NA, Not applicable.
∗
Comparison was done between White, African America/Black, Asian with Native American/Alaskan/Pacific Islander, and unknown.
†
Data from those who received the Janssen vaccine were excluded from inferential analysis.